XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 131 filers reported holding XENON PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,114,775 | -9.4% | 266,826 | +2.1% | 0.00% | – |
| Q2 2023 | $10,062,091 | +12.7% | 261,353 | +4.8% | 0.00% | – |
| Q1 2023 | $8,924,380 | +17.8% | 249,354 | +29.8% | 0.00% | – |
| Q4 2022 | $7,573,557 | +13.3% | 192,076 | +3.7% | 0.00% | – |
| Q3 2022 | $6,686,000 | +19.6% | 185,192 | +0.7% | 0.00% | – |
| Q2 2022 | $5,592,000 | +11.9% | 183,845 | +12.5% | 0.00% | – |
| Q1 2022 | $4,997,000 | +4.3% | 163,468 | +6.6% | 0.00% | – |
| Q4 2021 | $4,792,000 | +192.6% | 153,366 | +43.1% | 0.00% | – |
| Q3 2021 | $1,638,000 | -15.0% | 107,192 | +3.6% | 0.00% | – |
| Q2 2021 | $1,926,000 | +0.7% | 103,436 | -3.1% | 0.00% | – |
| Q1 2021 | $1,912,000 | +27.5% | 106,795 | +9.5% | 0.00% | – |
| Q4 2020 | $1,500,000 | +42.7% | 97,563 | +2.8% | 0.00% | – |
| Q3 2020 | $1,051,000 | -11.6% | 94,893 | +0.2% | 0.00% | – |
| Q2 2020 | $1,189,000 | – | 94,743 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 1,594,932 | $48,518,000 | 10.26% |
| GREAT POINT PARTNERS LLC | 1,104,334 | $33,594,000 | 8.06% |
| ACUTA CAPITAL PARTNERS, LLC | 272,500 | $8,289,000 | 4.62% |
| DAFNA Capital Management LLC | 438,623 | $13,343,000 | 3.64% |
| Parkman Healthcare Partners LLC | 294,559 | $8,960,000 | 3.30% |
| Avoro Capital Advisors LLC | 4,900,000 | $149,058,000 | 2.94% |
| Nan Fung Group Holdings Ltd | 114,380 | $3,479,000 | 2.39% |
| BVF INC/IL | 1,597,966 | $48,610,000 | 2.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 232,630 | $7,077,000 | 2.18% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 4,391,038 | $133,575,000 | 2.16% |